nodes	percent_of_prediction	percent_of_DWPC	metapath
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—FLI1—bone cancer	0.15	0.194	CbGpPWpGaD
Framycetin—CXCR4—Cardiac Progenitor Differentiation—T—bone cancer	0.134	0.173	CbGpPWpGaD
Framycetin—CXCR4—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.133	0.171	CbGpPWpGaD
Framycetin—CXCR4—S1P3 pathway—GNA11—bone cancer	0.0628	0.0812	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—RGS1—bone cancer	0.0427	0.0551	CbGpPWpGaD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—IL3—bone cancer	0.0391	0.0505	CbGpPWpGaD
Framycetin—Ototoxicity—Cisplatin—bone cancer	0.0387	0.171	CcSEcCtD
Framycetin—Malabsorption—Methotrexate—bone cancer	0.0294	0.13	CcSEcCtD
Framycetin—Nephrotoxicity—Cisplatin—bone cancer	0.0244	0.108	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—RGS1—bone cancer	0.0187	0.0242	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—GRM4—bone cancer	0.0187	0.0242	CbGpPWpGaD
Framycetin—CXCR4—Cardiac Progenitor Differentiation—KIT—bone cancer	0.0182	0.0235	CbGpPWpGaD
Framycetin—CXCR4—Syndecan-4-mediated signaling events—MMP9—bone cancer	0.0182	0.0235	CbGpPWpGaD
Framycetin—Secondary infection—Epirubicin—bone cancer	0.0136	0.0601	CcSEcCtD
Framycetin—Nephropathy toxic—Cisplatin—bone cancer	0.0135	0.0599	CcSEcCtD
Framycetin—Secondary infection—Doxorubicin—bone cancer	0.0126	0.0556	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GRM4—bone cancer	0.0113	0.0146	CbGpPWpGaD
Framycetin—Sensitisation—Epirubicin—bone cancer	0.0112	0.0495	CcSEcCtD
Framycetin—CXCR4—HIF-1-alpha transcription factor network—JUN—bone cancer	0.0105	0.0135	CbGpPWpGaD
Framycetin—Sensitisation—Doxorubicin—bone cancer	0.0103	0.0458	CcSEcCtD
Framycetin—Impaired healing—Methotrexate—bone cancer	0.00986	0.0437	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GRM1—bone cancer	0.00983	0.0127	CbGpPWpGaD
Framycetin—Infection—Carboplatin—bone cancer	0.00939	0.0416	CcSEcCtD
Framycetin—CXCR4—CXCR4-mediated signaling events—MMP9—bone cancer	0.0084	0.0108	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—SMO—bone cancer	0.00693	0.00895	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—RGS1—bone cancer	0.00641	0.00828	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GRM4—bone cancer	0.00641	0.00828	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—RGS1—bone cancer	0.00582	0.00752	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GRM4—bone cancer	0.00582	0.00752	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GRM1—bone cancer	0.00556	0.00718	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GRM1—bone cancer	0.00505	0.00652	CbGpPWpGaD
Framycetin—Viral infection—Epirubicin—bone cancer	0.00442	0.0196	CcSEcCtD
Framycetin—Viral infection—Doxorubicin—bone cancer	0.00409	0.0181	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GNA11—bone cancer	0.00358	0.00462	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—SMO—bone cancer	0.00356	0.00459	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RGS1—bone cancer	0.00344	0.00444	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GRM4—bone cancer	0.00344	0.00444	CbGpPWpGaD
Framycetin—Erythema—Cisplatin—bone cancer	0.0034	0.015	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—GNA11—bone cancer	0.00325	0.0042	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—IL3—bone cancer	0.00325	0.00419	CbGpPWpGaD
Framycetin—CXCR4—Disease—ENO2—bone cancer	0.00316	0.00409	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GRM1—bone cancer	0.00298	0.00385	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL3—bone cancer	0.00295	0.00381	CbGpPWpGaD
Framycetin—CXCR4—Disease—DHFR—bone cancer	0.00293	0.00379	CbGpPWpGaD
Framycetin—Anaphylactic shock—Cisplatin—bone cancer	0.00277	0.0123	CcSEcCtD
Framycetin—Infection—Cisplatin—bone cancer	0.00275	0.0122	CcSEcCtD
Framycetin—CXCR4—Disease—TGFBR2—bone cancer	0.00213	0.00275	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SMO—bone cancer	0.0021	0.00271	CbGpPWpGaD
Framycetin—Hypersensitivity—Cisplatin—bone cancer	0.00204	0.00905	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—GNA11—bone cancer	0.00192	0.00248	CbGpPWpGaD
Framycetin—Diarrhoea—Cisplatin—bone cancer	0.0019	0.0084	CcSEcCtD
Framycetin—Erythema—Methotrexate—bone cancer	0.00186	0.00826	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—ATF1—bone cancer	0.00179	0.00231	CbGpPWpGaD
Framycetin—Vomiting—Cisplatin—bone cancer	0.00176	0.00781	CcSEcCtD
Framycetin—Erythema—Epirubicin—bone cancer	0.00174	0.00773	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—IL3—bone cancer	0.00174	0.00225	CbGpPWpGaD
Framycetin—Nausea—Cisplatin—bone cancer	0.00165	0.00729	CcSEcCtD
Framycetin—Erythema—Doxorubicin—bone cancer	0.00161	0.00715	CcSEcCtD
Framycetin—Anaphylactic shock—Methotrexate—bone cancer	0.00152	0.00674	CcSEcCtD
Framycetin—Infection—Methotrexate—bone cancer	0.00151	0.00669	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—TGFBR2—bone cancer	0.00149	0.00192	CbGpPWpGaD
Framycetin—CXCR4—Disease—KIT—bone cancer	0.00145	0.00187	CbGpPWpGaD
Framycetin—Anaphylactic shock—Epirubicin—bone cancer	0.00142	0.0063	CcSEcCtD
Framycetin—Infection—Epirubicin—bone cancer	0.00141	0.00626	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—IGF1R—bone cancer	0.0014	0.00181	CbGpPWpGaD
Framycetin—CXCR4—Disease—BRAF—bone cancer	0.00136	0.00176	CbGpPWpGaD
Framycetin—Anaphylactic shock—Doxorubicin—bone cancer	0.00132	0.00583	CcSEcCtD
Framycetin—Infection—Doxorubicin—bone cancer	0.00131	0.0058	CcSEcCtD
Framycetin—CXCR4—Disease—MDM2—bone cancer	0.00114	0.00148	CbGpPWpGaD
Framycetin—Hypersensitivity—Methotrexate—bone cancer	0.00112	0.00496	CcSEcCtD
Framycetin—CXCR4—Disease—PTGS2—bone cancer	0.0011	0.00142	CbGpPWpGaD
Framycetin—Pruritus—Methotrexate—bone cancer	0.00108	0.00477	CcSEcCtD
Framycetin—Hypersensitivity—Epirubicin—bone cancer	0.00105	0.00465	CcSEcCtD
Framycetin—Diarrhoea—Methotrexate—bone cancer	0.00104	0.00461	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—KIT—bone cancer	0.00102	0.00131	CbGpPWpGaD
Framycetin—Pruritus—Epirubicin—bone cancer	0.00101	0.00446	CcSEcCtD
Framycetin—Diarrhoea—Epirubicin—bone cancer	0.000974	0.00431	CcSEcCtD
Framycetin—Hypersensitivity—Doxorubicin—bone cancer	0.00097	0.0043	CcSEcCtD
Framycetin—Vomiting—Methotrexate—bone cancer	0.000967	0.00428	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—BRAF—bone cancer	0.000955	0.00123	CbGpPWpGaD
Framycetin—Pruritus—Doxorubicin—bone cancer	0.000932	0.00413	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—EGFR—bone cancer	0.000926	0.0012	CbGpPWpGaD
Framycetin—Vomiting—Epirubicin—bone cancer	0.000905	0.00401	CcSEcCtD
Framycetin—Nausea—Methotrexate—bone cancer	0.000904	0.004	CcSEcCtD
Framycetin—Diarrhoea—Doxorubicin—bone cancer	0.000901	0.00399	CcSEcCtD
Framycetin—Nausea—Epirubicin—bone cancer	0.000846	0.00375	CcSEcCtD
Framycetin—Vomiting—Doxorubicin—bone cancer	0.000837	0.00371	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—MDM2—bone cancer	0.0008	0.00103	CbGpPWpGaD
Framycetin—Nausea—Doxorubicin—bone cancer	0.000782	0.00347	CcSEcCtD
Framycetin—CXCR4—Disease—EGFR—bone cancer	0.000781	0.00101	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—JUN—bone cancer	0.000696	0.000899	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MMP9—bone cancer	0.000677	0.000874	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EGFR—bone cancer	0.000547	0.000706	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TP53—bone cancer	0.000459	0.000593	CbGpPWpGaD
